Year :
2019
| Month :
February
| Volume :
13
| Issue :
2
| Page :
OD04 - OD05
Full Version
Recurrent Stroke in a Young Adult due to Antiphospholipid Antibody Syndrome-A Case Report
Published: February 1, 2019 | DOI: https://doi.org/10.7860/JCDR/2019/38468.12534
Siraveni Thirupathi, Dinesh Ragav, Nasreen Begum
1. Postgraduate, Department of General Medicine, Shri Sathya Sai Medical College and Research Institute, Kancheepuram, Tamil Nadu, India.
2. Assistant Professor, Department of General Medicine, Shri Sathya Sai Medical College and Research Institute, Kancheepuram, Tamil Nadu, India.
3. Professor, Department of General Medicine, Shri Sathya Sai Medical College and Research Institute, Kancheepuram, Tamil Nadu, India.
Correspondence Address :
Dr. Dinesh Ragav,
Assistant Professor, Shri Sathya Sai Medical College and Research Institute, Ammapetti, Nellikuppam, Sembakkam (Taluka),
Kancheepuram, Tamil Nadu, India.
E-mail: drthiruyadav@gmail.com
Abstract
Antiphospholipid Syndrome (APS) is an autoimmune disease characterised by arterial thrombosis, venous thromboembolic complications, mild to moderate thrombocytopenia and/or pregnancy morbidities in the presence of persistently positive levels of antiphospholipid antibodies (aPL) such as Lupus Anticoagulant (LA), anticardiolipin (aCL), and anti-ß2-glycoprotein-I (aß2GPI) antibodies. Many mechanisms create a prothrombotic state, it is prone to complication like abortions, preterm deliveries, foetal loss, cerebral stroke, acute coronary syndrome, venous thromboembolic and peripheral vascular occlusive disorders, intracerebral haemorrhage, encephalopathy and infections. Here, the case of a 42-year-old female is being reported, who was diagnosed with APS, treated with warfarin. The available knowledge about this disease and its relevance to the symptoms of the patient is also summarised.
Keywords
Lupus anticoagulant, Procoagulable state, Thromboembolic events
DOI: 10.7860/JCDR/2019/38468.12534
Date of Submission: Aug 31, 2018
Date of Peer Review: Oct 17, 2018
Date of Acceptance: Nov 20, 2018
Date of Publishing: Feb 01, 2019
FINANCIAL OR OTHER COMPETING INTERESTS: None.
|